These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 19382081)

  • 1. [Why does a patient on hemodialysis have radiopaque material in his abdomen?].
    Aucella F; Marinelli T; Paoletti D; Vigilante M; Vocino V
    G Ital Nefrol; 2009; 26(2):246-9. PubMed ID: 19382081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Radiographic characteristics of lanthanum carbonate absorption].
    Vrigneaud L; Lefèbvre D; Daem AO; Lemaitre V
    Nephrol Ther; 2008 Apr; 4(2):111-3. PubMed ID: 18243834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Nodular Foreign Body Reaction in a Dialysis Patient Receiving Long-term Treatment With Lanthanum Carbonate.
    Valika AK; Jain D; Jaffe PE; Moeckel G; Brewster UC
    Am J Kidney Dis; 2016 Jan; 67(1):128-32. PubMed ID: 26385816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
    Altmann P; Barnett ME; Finn WF;
    Kidney Int; 2007 Feb; 71(3):252-9. PubMed ID: 17035945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Starry-sky bowels.
    Chang FM; Tarng DC; Yang CY
    Int J Colorectal Dis; 2018 Dec; 33(12):1807-1808. PubMed ID: 30280253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lanthanum masquerading as foreign body ingestion in a critically ill patient with end-stage renal disease.
    Rappaport SH; Vineyard T; Hack M; Shah T; Dooley JW
    Am J Health Syst Pharm; 2023 Mar; 80(7):430-434. PubMed ID: 36566498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
    Albaaj F; Hutchison AJ
    Int J Clin Pract; 2005 Sep; 59(9):1091-6. PubMed ID: 16115187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
    Joki N
    Clin Calcium; 2009 Feb; 19(2):213-8. PubMed ID: 19182361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Radiology image of lanthanum carbonate].
    Díez Ojeda B; Medrano Martínez S; Alonso Alvarez MA
    Nefrologia; 2010; 30(2):263-4. PubMed ID: 20393629
    [No Abstract]   [Full Text] [Related]  

  • 14. [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
    Koiwa F; Sato Y
    Clin Calcium; 2009 Feb; 19(2):198-204. PubMed ID: 19182359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
    Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanthanum carbonate has a radiopaque appearance on the plain abdominal radiography.
    Ruiz Pardo J; Ibáñez Cánovas N; Abrisqueta Carrión J; Luján Mompeán JA; Parrilla Paricio P
    Rev Esp Enferm Dig; 2016 Jun; 108(6):365-6. PubMed ID: 27324519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lanthanum carbonate in clinical practice].
    Torregrosa Prats V
    Nefrologia; 2008; 28 Suppl 5():11-4. PubMed ID: 18847414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy.
    Chan MR; Yevzlin AS; Hinshaw M; Jaffery JB
    WMJ; 2008 Nov; 107(7):335-8. PubMed ID: 19180873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.